Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for MIBC
NCT06809140Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in muscle-invasive bladder cancer (MIBC). Started Apr 2025; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06809140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809140.